News - Allergan, Neurological

Filter

Current filters:

AllerganNeurological

Popular Filters

Review of key drivers of migraine market growth through 2022

06-12-2013

Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

FDA sends CRL rejecting Allergan's migraine drug Levadex on quality issues

17-04-2013

US drugmaker Allergan (NYSE: AGN) said yesterday (April 16) that the US Food and Drug Administration…

AllerganLevadexNeurologicalNorth AmericaPharmaceuticalProductionRegulation

Allergan to acquire MAP Pharmaceuticals in $958 million deal

24-01-2013

US drugmaker Allergan (NYSE: AGN) has entered into a definitive merger agreement to acquire 100% of the…

AllerganLevadexMAP PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceutical

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

FDA delay for MAP Pharma migraine drug candidate

28-03-2012

Shares of USA-based MAP Pharmaceuticals (Nasdaq: MAPP) plunged 24% to $13.01 in early trading yesterday,…

AllerganLevadexMAP PharmaceuticalsMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulation

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

Allergan gets US FDA nod for Botox to treat form of urinary incontinence

25-08-2011

There was a boost for US specialty drug firm Allergan (NYSE: AGN) yesterday when the company revealed…

AllerganBotoxNeurologicalNorth AmericaPharmaceuticalRegulation

MAP Pharma gets $20 million milestone as US FDA accepts Levadex NDA

03-08-2011

California, USA-based MAP Pharmaceuticals (Nasdaq: MAPP) says that its New Drug Application for Levadex…

AllerganLevadexMAP PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top